Carregando...
Impact of dose‐escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model‐based approach
AIMS: To investigate the impact on weight loss of the treatment changes in overweight or obese people that may be needed in case of gastrointestinal (GI) tolerability issues during escalation of the glucagon‐like peptide‐1 analogue liraglutide. MATERIALS AND METHODS: The individual longitudinal body...
Na minha lista:
| Publicado no: | Diabetes Obes Metab |
|---|---|
| Principais autores: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Blackwell Publishing Ltd
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7317899/ https://ncbi.nlm.nih.gov/pubmed/32009288 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13985 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|